CARB-X is a non-profit partnership
CARB-X is funded by the Wellcome Trust in the United Kingdom, the United States Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR), and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The UK Government’s Department of Health and Social Care (DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF) has been a CARB-X funding partner since May 2018. The Bill and Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, is a CARB-X Alliance Partner since May 2018. CARB-X operates through Boston University. With funds from its Funding and Alliance Partners, CARB-X is investing more than $500 million from 2016-2021 to accelerate the development of innovative antibiotics and other therapeutics, vaccines, rapid diagnostics and devices to address drug-resistant bacterial infections.
Business, technical and scientific support for CARB-X-funded companies is provided in partnership with CARB-X accelerators. They include the California Life Sciences Institute (CLSI), RTI International, the Broad Institute of Harvard and MIT, MassBio, and the Defense Threat Reduction Agency (DTRA), part of the US Department of Defense.